載入...
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
Daily vs. weekly dosing with EGFR inhibitors (gefitinib and lapatinib) and an AKT inhibitor (MK2206) were compared in two rodent breast cancer models. Female Sprague-Dawley rats were administered methylnitrosourea (MNU) at 50 days of age, and gefitinib (daily/weekly dosing at 10/70 mg/kg BW) or lapa...
Na minha lista:
| 發表在: | Oncol Rep |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
D.A. Spandidos
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6072405/ https://ncbi.nlm.nih.gov/pubmed/29565450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2018.6313 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|